171 results about "Liver fat" patented technology

The present invention provides a composition for a medicinal or health effect of a treatment of liver fat and body fat, a reduction of blood pressure, an increase of the energy expenditure rate, a reduction of inflammatory C-reactive proteins and a reduction of plasma aminotransferase enzymes, comprising an effective amount of fucoxanthin alone or in combination with pomegranate seed oil, a pharmaceutically acceptable salt, a prodrug thereof, or a salt of the prodrug; and a method of using the same. The fucoxanthin may be used in pure form, or as a component of a brown marine vegetable extract.

Methods for measuring liver fat mass are provided. One method includes acquiring dual-energy two-dimensional (2D) scan information from a dual-energy X-ray scan of a body and generating a dual-energy X-ray image of the body using the 2D scan information. The method further includes identifying a region of interest using the dual-energy X-ray image and determining a subcutaneous fat mass for each of a plurality of sections of the region of interest. The method also includes determining a liver fat mass for the region of interest based on the determined subcutaneous fat mass for each of the plurality of sections.

The invention provides compositions comprising a pharmaceutical compound having one or more Microsomal Triglyceride Transfer Protein (MTP) inhibitors that are covalently linked to one or more Liver Fatty Acid-Binding Protein (L-FABP) inhibitors. Also disclosed are methods for using the inventive pharmaceutical compositions in the treatment of hepatic steatosis and hyperlipidemia while avoiding the harmful side effects of steatorrhea.

Evidence is emerging that lipid accumulation in the liver and the muscle contributes to insulin resistance in type II diabetes and the metabolic syndrome (1). This has prompted an investigation of the relationship between lipid accumulation in the liver, serum triglyceride levels, and glucose disposal. These studies demonstrate that liver fat positively correlated to fasting triglyceride levels and negatively correlated to glucose diposal (2). Therefore, strategies to prevent lipid accumulation in liver would have therapeutic value for treatment of type II diabetes, metabolic syndrome and non-alcoholic fatty liver disease. The invention described here relates to continuous administration of GLP-1 or its analogs obtained by either gene or cell therapy that results in reduction serum triglycerides and reduction of lipid accumulation in the liver for treatment of type II diabetes, the metabolic syndrome or non-alcoholic fatty liver disease.

An apparatus, method, and computer program product for calibrating a CT scan without the use of an external calibration phantom, to enable quantitative assessment of internal body tissues and organs and additionally for any application that would benefit from a calibration of the scan attenuation data, such as viewing CT images in a consistent fashion. Embodiments are described with applications to quantitative assessment of bone density in the spine and hip, mineral content in blood vessels, hepatic-fat content in the liver, and gray-to-white matter ratio in the brain. The primary advantages of the method are that it does not require the use of an external calibration phantom, it is robust across different CT machines and scanner settings, and it is also highly precise, lending itself to a high degree of automation.

The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium / glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.

The invention discloses a healthcare feed used for grass carps to overwinter and a preparation method for the healthcare feed. The healthcare feed comprises the following components in percentage by weight: 0.0003 to 0.0075 percent of ferrous sulfate, 0.00003 to 0.00025 percent of anhydrous cupric sulfate, 0.0002 to 0.002 percent of zinc sulfate, 0.0002 to 0.0004 percent of vitamin A, 0.0001 to 0.0004 percent of vitamin D3, 0.5 to 2 percent of calcium dihydrogen phosphate, 5 to 25 percent of soya bean meal, 3 to 8 percent of alfalfa meal, 3 to 10 percent of fish meal, 0.05 to 0.08 percent of bile acid, 1 to 3 percent of seaweed powder and 100 percent of flour. The healthcare feed provided by the invention meets requirements of fish bodies for nutrition by selecting imported fish meal and soya bean meal, improves the intestinal environment of fish by adding high-quality dietary fibers such as the alfalfa meal and the like, and reduces liver fat accumulation of the grass carps by addingadditives such as the bile acid and the like, so that fish is more healthy; therefore, the stress bleeding when the grass carps are sold can be reduced and the grass carps can overwinter safely.

A liver fat qualitative measurement method based on an ultrasonic attenuation coefficient belongs to technical field of signal processing and liver fat attenuation coefficients. The method comprises the steps of: measuring the liver fat content of fatty liver patients at different stages; carrying out scanning to acquire ultrasonic echo signals at different frequencies, i.e. f1 and f2; performing detection on the ultrasonic echo signals by using Hilbert transform; performing time-frequency analysis on the detected signals by using short-time Fourier transform; calculating an average of amplitudes corresponding to different frequencies at each sampling moment; performing logarithm transform on the average at each sampling point; then making a different between two sets of data corresponding points; performing linear fitting on 50 successive points to obtain a straight line slope; and finally obtaining an attenuation coefficient of the corresponding points. The method can be used for performing real-time and precise attenuation coefficient calculation on liver tissues; and eventually, a model is established by means of a corresponding relationship between the liver fat content and the liver ultrasonic attenuation coefficient, and the liver fat content is estimated by calculating the ultrasonic attenuation coefficient of the liver, so as to realize non-invasive measurement of the liver fat content.

An apparatus for measuring liver fat content and / or iron content non-invasively in vivo using unilateral NMR technology is disclosed. The apparatus comprises a unilateral NMR probe positioned against or in the proximity of the body. The probe generates static and RF magnetic fields to measure NMR signals at selected depths into the body. The apparatus further comprises a unilateral magnet and a unilateral antenna placed between a magnet and the body or around the magnet. The unilateral antenna is used to attain NMR signals. The measurement of NMR signals at a single position with a single frequency determines fat content on a specific volume inside the liver. The measurement of NMR signals at a single position with two or more frequencies determines iron content on a specific volume inside the liver.

The invention relates to a liver fat detection system based on ultrasound. An ultrasound generator transmits pulse ultrasound to the liver. An ultrasonic receiver receives an echo signal of the ultrasound. An ultrasound echo luminance level value obtaining module obtains the luminance level value of a far-field region of the liver and obtains the luminance level value of a near-field region of the liver. An ultrasound attenuation coefficient obtaining module obtains the echo attenuation coefficient of the liver. An ultrasound attenuation coefficient compensation module obtains a modified ultrasound attenuation coefficient by setting up standard liver die bodies with different thicknesses and through ultrasound attenuation coefficient compensation. A liver fat detection module sets up the corresponding relation between the liver fat content and the ultrasound echo signal through measurement, and obtains the liver fat content according to the ultrasound attenuation coefficient obtained through compensation. According to the technical scheme, the image luminance level values are obtained through the ultrasound echo signal of the liver, the echo attenuation coefficient of the liver is more accurately calculated, the ultrasound attenuation coefficient is compensated for by setting up the standard liver die bodies, the corresponding relation between the liver fat content and the ultrasound echo signal is set up, and the liver fat content is obtained according to the ultrasound attenuation coefficient obtained through compensation. According to the technical scheme, the liver fat detection system is convenient and easy to use, practical, accurate and reliable.

The invention relates to a Chinese herbal medicine for treatment of fatty liver and its preparation method. It is characterized in that composition ratio by weight is: Herba Artemisiae Scopariae 2-3, fructus gardeniae 0.6-1, radix et rhizoma rhei 0.6-1, semen cassiae 2-3, rhizoma polygoni cuspidate1.5 -2, radix polygoni multiflori 2-3, rhizoma alismatis2-3, radix et rhizoma salviae miltiorrhizae 1.5-2. fructus crataegi 2-3, rhizoma curcumae longae 1-1.5, radix ginseng 0.6-1, herba gynostemmae pentaphylli 2-3, alog 0.15-0.2.The preparation method: choose materials by weight; radix et rhizoma rhei, semen cassiae , radix ginseng , rhizoma curcumae longae , radix polygoni multiflori materials were porphyrized into powder, herba artemisiae scopariae, fructus gardeniae, rhizoma polygoni cuspidate, rhizoma alismatis, radix et rhizoma salviae miltiorrhizae, fructus crataegi, radix ginseng, herba gynostemmae pentaphylli materials were decocted and boiled to get the filtrate, concentration was obtained, the power-thick paste made grain were dried. The invention can lower the blood-fat, resist to preoxidative damage, significantly improve the liver-fat metabolism, confront fatty liver and nourish the liver and of lipid-lowering effects, with low toxicity, high security, can delay or prevent fibrosis and cirrhosis of liver.

The invention discloses a feed additive for reducing the freshwater fish body fat content and a preparation method thereof. The feed additive is prepared from clofibrate, soybean oil and a zeolite powder in a certain proportion. The preparation method comprises the steps: A, crushing the zeolite powder to pass through a 70-90 mesh sieve, and weighing the components of clofibrate, the soybean oil and the zeolite powder in proportion; B, mixing uniformly clofibrate and the soybean oil, then mixing uniformly with the zeolite powder in a mixing machine, and making the variation coefficient of the mixture not more than 5%, wherein the mixture is the feed additive for reducing the freshwater fish body fat content. The method is simple to implement, convenient to operate, and obvious in effect; the product with the amount of 0.5-1.5% is added into a freshwater fish feed, after feeding for 9 weeks, the freshwater fish body fat content can be significantly reduced by 16-25%, the liver fat content can be reduced by 6-11%, the abdominal fat content can be reduced by 22-35%, generation of related diseases can be effectively prevented from being induced because of excessive accumulation of the fish body fat in freshwater aquaculture, and the healthy and sustainable development of the freshwater aquaculture is promoted.

The invention provides a feed for pork rich in omega-3 fatty acid and a preparation method thereof, which is characterized in that the feed improves omega-3 fatty acid content ratio in pig intramuscular fat, back fat, abdomen fat as well as heart and liver fat for 3-7 times, and pork rich in omega-3 fatty acid is not easy to oxidize and has long storage time. The feed is prepared by the following componets 10% of flaxseed, VE 200 / kg diet and 1% of Chinese herbal medicine are added in formulating diet, wherein the Chinese herbal medicine is prepared by fructus ligustri lucidi and Astragalus mongholicus at the ratio of 1: 1. The method comprises the following steps: screening flaxseed, selecting VE, preparing compound Chinese herbal medicine, providing a diet formula, and preparing diet. The feed disclosed by the invention can improve omega-3 fatty acid content ratio in pig intramuscular fat, back fat, abdomen fat as well as heart and liver fat for 3-7 times, and pork rich in omega-3 fatty acid is not easy to be oxidized and has long storage time.

The invention relates to a liver fat quantitative system based on ultrasonic. The liver fat quantitative system comprises an ultrasonic generator, an ultrasonic receiver, an ultrasonic echo brightness level value acquisition module, an ultrasonic attenuation coefficient acquisition module, an intensity ratio acquisition module for acquiring the liver and kidney echo intensity ratio H, and a liver fat quantitative module. The ultrasonic generator transmits pulse ultrasonic to the liver; the ultrasonic receiver receives echo signals of ultrasonic; the ultrasonic echo brightness level value acquisition module acquires a brightness level value of a liver far field region and a brightness level value of a near field region; the ultrasonic attenuation coefficient acquisition module acquires liver echo attenuation coefficients, and liver fat quantitative detection is conducted through the liver and kidney echo intensity ratio H and the liver echo attenuation coefficients. According to the technical scheme, the liver echo attenuation coefficients can be more accurately calculated through the image brightness level value acquired by the liver ultrasonic echo signals, and the liver fat quantitative detection is conducted through the liver and kidney echo intensity ratio H and the liver echo attenuation coefficients. The liver fat quantitative system is convenient and easy to use, practical, accurate and reliable.

The invention relates to an artificial compound feed capable of improving exceptional fatty deposition of the liver of larimichthys crocea. The artificial compound feed comprises the following components of 30-40 parts of fish meal, 25-30 parts of soybean meal, 20-25 parts of wheat flour, 1.5-3 parts of fish oil, 1.5-3 parts of linseed oil, 1.5-3 parts of soybean oil, 1.5-3 parts of lard, 1.5-3 parts of chicken oil, 1-2 parts of soybean lecithin, 1-3 parts of a vitamin premix, 1-3 parts of a mineral premix, 0.08-0.12 part of a phagostimulant, 0.08-0.12 part of a mildewproof agent and 0.05-0.11part of carnitine. According to the artificial compound feed, the growth, the antioxidase vitality and the fat utilization efficiency of the young larimichthys crocea can be effectively promoted, theexceptional liver fat condition can be improved, the breeding benefits can be increased, the feed cost can be saved, and the breeding economic benefits are high.

The invention discloses a preparation method for a non-alcoholic fatty liver disease zebra fish. The method comprises the steps that a zebra fish is cultured in high-fat nutrient solution which contains 50-200mu M of palmitic acid and 100-400mu M of oleic acid, and whether the non-alcoholic fatty liver disease zebra fish is successfully constructed or not is judged according to a final liver fat titer of the zebra fish. The preparation method is characterized in that the zebra fish is adopted to construct the non-alcoholic fatty liver disease zebra fish model for the first time in China, cost is low, a mature period is short, and pathology and drug screening cost can be effectively lowered. In addition, a zebra fish model can be used for constructing a high-flux medicine screening platform to further improve biological medicine development efficiency. The achievement of the scheme provides reference for the pathology of the occurrence of the clinical non-alcoholic fatty liver disease, and the formed zebra fish model is provided for various scientific research institutions and pharmaceutical companies, and becomes a powerful tool for the pathological study of the non-alcoholic fatty liver disease, the development of a novel treatment means and the high-flux screening of medicines.

The invention discloses an application of Soracan gum in reducing liver fat, blood fat, body fat, body weight and cholesterol, which comprises the following steps: firstly preparing a culture solution, and heating the culture solution for sterilization; adding a plate colony solution to the cooled culture solution; placing the culture solution in a shaking table for fermentation, and forming the culture solution into a seed culture solution; cooling the obtained culture solution, adding to the obtained the seed culture solution, and fermenting in the shaking table to obtain a viscous metabolite; injecting ethanol or acetone into the obtained fermentation liquid, and depositing, wherein the volume of the ethanol or acetone is at least twice of that of the fermentation liquid; and drying the obtained precipitate in vacuum to obtain a crude Soracan gum product. Taking the crude Soracan gum product alone or taking the crude Soracan gum product with food can reduce liver fat, blood fat, body fat, body weight and cholesterol. The Soracan gum has the advantages of high output and simple and convenient extraction method, can be directly dissolved in cold water, can effectively reduce indexes such as liver fat, blood fat, body fat, body weight, cholesterol and the like, is safe and nontoxic and can be directly eaten.

The invention belongs to the field of biotechnology, and relates to an experimental animal model for transforming nonalcoholic steatohepatitis into liver cancer. In particular, a large and mouse model of nonalcoholic chronic steatohepatitis (NASH) and chronic steatohepatitis developing into chronic liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) can be used for chronic fatty Liver, steatohepatitis, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, metabolic diseases, diabetes, in vivo experiments of related mechanisms of diabetic complications, new drug development, and non-alcoholic steatohepatitis (NASH), liver It has extremely high application value in the study of the pathogenesis of fibrosis and liver cancer and in drug development.

The invention provides an ultrasonic-based liver fat quantification method and system. According to recommendations, the system comprises an ultrasonic transmitter, an ultrasonic receiver, an ultrasonic signal processing module, a liver near-field positioning module, a liver far-field positioning module and an ultrasonic attenuation coefficient calculating module; the ultrasonic transmitter is used for transmitting pulse ultrasonic to liver tissues; the ultrasonic receiver is used for receiving ultrasonic echo signals of the liver tissues; the ultrasonic signal processing module is used for compensating, sampling, demodulating, envelope detecting or filtering of the ultrasonic echo signals of the liver tissues, so as to obtain processed ultrasonic echo corrected signals; the liver near-field positioning module is used for positioning a near-field region RN of a liver; the liver far-field positioning module is used for positioning a far-region of the liver; the ultrasonic attenuation coefficient calculating module is used for calculating an ultrasonic attenuation coefficient Epsilon of the liver.

The present invention discloses a functional food for conditioning fatty liver. The food is prepared from the following raw materials by weight: 20-40 parts of siberian solomonseal rhizome extract, 20-40 parts of lotus leaf extract, 20-40 parts of lobed kudzuvine root extract and 10-40 parts of red kojic rice powder. In the present invention, the several raw materials have respective functions, besides, the raw materials are blended together to form the food, which is proved by experiment rich in metabolic balance factor for human fatty liver, having functions of effectively preventing the intestinal absorption of excessive fat, effectively regulating the liver fat metabolic function, promoting the full oxidation of blood fatty acids, effectively blocking the synthesis of TG, reducing the concentration of fat in liver, removing the "sleeping fat" in liver cells, reversing the fatty liver and maintaining the metabolic balance of liver fat, and completely non-toxic side effects.

The present invention relates to the technical field of medicine, particularly to an application of a glucosamine salt. The weight reduction and / or fat reduction drug prepared by adopting the glucosamine salt, especially the drug with effects of weight reduction and fat reduction, provides significant application effects in fields of weight control, appetite ensuring, body fat reduction and liver fat metabolism acceleration. Application research results show that the glucosamine hydrochloride provides more excellent corresponding effects compared with the glucosamine sulfate. The present invention provides the new application of the glucosamine salt, wherein the glucosamine salt has effects of significant weight reduction, significant fat reduction, fatty liver alleviating and serum blood fat reduction.

The invention relates to a product made from rosemary extract for treating alcoholic livers and fatty livers, and a processing technology of the product. According to the invention, fat-soluble extracts and water-soluble extracts of rosemary are processed through an ultra-low temperature extraction technology in modern biology, and are formulated and combined into finished products. The extracts are prepared through a series of technologies: an ultrasonic countercurrent and membrane separation (molecular sieve) technology, a membrane separation (molecular sieve) technology, and a macroporous resin adsorption technology. With the technologies, high contents of fat-soluble and water-soluble extracts are obtained from rosemary. The product is stable in quality, safe in use, and provides substantial curative effects against alcoholic livers and fatty livers.

The invention relates to an ultrasonic attenuation coefficient compensation system and a liver fat detection system. An ultrasonic generator transmits pulse ultrasonic waves to the liver, an ultrasonic receiver receives echo signals of the ultrasonic waves, an ultrasonic attenuation coefficient obtaining module obtains a liver echo attenuation coefficient, a center frequency compensation module builds standard liver models in different thicknesses, an ultrasonic attenuation coefficient of the standard liver model in the corresponding thickness is measured, center frequencies of the standard liver models in different thicknesses are obtained through calculation, when the liver echo attenuation coefficient is measured, compensation is conducted at the center frequency of the model in the corresponding thickness so as to obtain a compensated ultrasonic attenuation coefficient, and quantitative detection is conducted on liver fat through the liver and kidney echo strength ratio H and the liver echo attenuation coefficient. According to the ultrasonic attenuation coefficient compensation system and the liver fat detection system, an image brightness level value is obtained through the liver ultrasonic echo signals, the liver echo attenuation coefficient is calculated more accurately, and then quantitative detection is conducted on liver fat through the liver and kidney echo strength contrast and the liver echo attenuation coefficient.

The present invention is based on the idea of determining certain molecular lipids from a subject's blood sample, for example from serum or plasma sample, and based on the amounts of the determined lipids determining the amount of liver fat and / or diagnosing NAFLD in the subject. More specifically the subjects with elevated liver fat amount and NAFLD are characterized by elevated triglycerides with low carbon number and double bond content in the blood sample. Lysophosphatidylcholines, ether phospholipids, sphingomyelins and PUFA-containing phospholipids are diminished in the blood samples of subjects with an elevated liver fat amount and NAFLD. The method of the present invention can be further used for monitoring the subject's response to the treatment of NAFLD or to the treatment of lowering of the liver fat amount in the subject.

The invention discloses fu tea extract and application thereof in regulating blood lipid and liver fat. The method for preparing the fu tea extract comprises the following steps that with fu tea beinga raw material, organic solvent or CO2 is used for extraction, and after the extraction is completed, the fu tea extract is obtained. A medicine effect test shows that after the fu tea extract is therapeutically applied to a model of ICR mice fed by high-fat feed for four weeks, when the tested extract is at the high dosage of 500 mg / kg, the fu tea extract has the obvious effects on lowering blood lipid relevant important indexes of total cholesterol, triglyceride and low density lipoprotein cholesterin in serum; when at the dosage of 200 mg / kg-500 mg / kg, the extract has the obvious effect onlowering mouse liver fat relevant indexes of total cholesterol and triglyceride and basically has no toxic and side effect. The fu tea extract has very large application potential in the aspects of preparing lipid-lowering drugs.

The invention relates to a fatty liver detecting system based on an ultrasonic attenuation coefficient, and belongs to the technical field of signal processing and liver attenuation coefficients. Thefat contents of livers of patients with different degrees of fatty liver are measured, a lower computer acquires an ultrasonic echo signal and uploads the ultrasonic echo signal to an upper computer,gain of an original signal is removed at first, then the signal is subjected to band-pass filtering to remove interference noises, a filter signal is subjected to envelope detection by hilbert transform, then the detected signal is subjected to logarithm transformation, after data are obtained, the data are subjected to smoothing filtering and down-sampling, all continuous points are subjected tolinear fitting to solve straight slope, finally, an attenuation coefficient which corresponds to the data is solved, in the calculating process, the fat content in the liver is measured by calculatingthe attenuation degree of the ultrasonic echo signal in human body liver fat, and the fatty liver detecting system based on the ultrasonic attenuation coefficient can be used for measuring the attenuation coefficient of liver tissues and detecting the degree of fatty liver.

The invention discloses a fattening pig feed without bean pulp and calcium hydrophosphate, which is prepared through the following components in percentage by weight: 67.4% of corn, 30.00% of corn DDDGS, 1.22% of mountain flour, 0.30% of salt, 0.33% of lysine with effective content of more than 98%, 0.02% of tryptophan with effective content of more than 98%, 0.07% of threonine with effective content of more than 98%, 0.1% of choline chloride with effective content of more than 50%, 0.2% of trace element premix, 0.02% of vitamin premix, 0.04% of vitamin E and 0.3% of sodium selenite. Side effects of low growing speed of pigs, quality reduction of pork and short storage period caused by highly-added corn DDDGS are eliminated and the content of unsaturated fatty acid in intramuscular fat, back fat, abdominal fat and liver fat can be increased, the oxidation resistance of muscular tissues can be improved and the storage time of pork can be prolonged to 3-5 days.

The invention relates to a medicament for treating chronic hepatitis and early-phase hepatocirrhosis and a preparation method thereof. The medicament is characterized by consisting of largehead atractylodes rhizome (fried), nutgrass galingale rhizome (processed), white paeony root, zedoary, common burreed rhizome, Chinese angelica, papaya, rhubarb, safflower, turtle shell (roasted), peach seed, turmeric root-tuber, virgate wormwood herb, seaweed, kelp, figwort root, rehmannia root, prepared rehmannia root, giant knotweed, ground beetle, bupleurum, tuber fleeceflower root (processed), Chinese trumpetcreeper flower, dung beetle, trogopterus dung, black bean and Chinese lobelia herb. The method comprises the following steps of: smashing raw materials according to the composition and weight ratio; continuously refluxing and extracting; concentrating the extract; and drying and smashing the condensate to obtain the medicament. The medicament has the remarkable advantages of improving liver fat metabolism and the organization structure of a pathologic liver, protecting the liver, remarkably saving water and steam by over 50 percent, reducing drying time, keeping the functions of the raw materials, contributing to absorbing, along with high bioavailability, high active ingredient content, low energy consumption, easy operation and the like.

The invention discloses application of ((i) lactobacillus johnsonii( / i)) BS15 with collection number of CCTCC NO:M2013663 in preventing and treating non-alcoholic fatty liver (NAFLD) caused by high-fat food. The lactobacillus johnsonii BS15 remarkably lowers degeneration degree of fat mouse liver fat and apoptosis rate of liver cells.

The invention discloses a postbiotic prepared from lactobacillus rhamnosus and used for relieving fatty liver and obesity and application of the postbiotic, and belongs to the technical field of microorganisms and the technical field of medicines. The metagen prepared from the rhamnobacter rhamnosus CCFM1219 provided by the invention has the effects of relieving fatty liver and obesity: (1) the weight gain of high-fat diet mice is obviously relieved; (2) the blood glucose steady state of high-fat diet mice is obviously improved; (3) the liver fat accumulation and lesion of the high fat diet mouse are obviously inhibited; (4) the size of white fat cells is obviously reduced, the normal form of brown fat is maintained, and the browning of the white fat is promoted; (5) the levels of serum TC, GGT and ALP of high-fat diet mice are obviously reduced; and (6) the weight of white adipose tissues of the liver and the abdomen of the high-fat diet mouse is effectively reduced. Therefore, the metagen prepared from the lactobacillus rhamnosus CCFM1219 has a huge application prospect in preparation of products for preventing and / or treating fatty liver and obesity and even preventing and / or treating obesity and metabolic disorder related diseases.